Florent Guelfucci1, Yuko Kaneko2, Jörg Mahlich3,4, Rosarin Sruamsiri5,6. 1. Creativ-Ceutical, Paris, France. 2. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. 3. Health Economics, Janssen Pharmaceutical KK, Tokyo, Japan. joerg.mahlich@gmail.com. 4. Düsseldorf Institute for Competition Economics (DICE), University of Düsseldorf, Düsseldorf, Germany. joerg.mahlich@gmail.com. 5. Health Economics, Janssen Pharmaceutical KK, Tokyo, Japan. 6. Center of Pharmaceutical Outcomes Research, Naresuan University, Phitsanulok, Thailand.
Abstract
INTRODUCTION: To determine the cost of depression comorbidity among Japanese adults with rheumatoid arthritis (RA). METHODS: A retrospective database study of 8968 patients diagnosed with RA between 2010 and 2015 and treated with any RA medication was conducted. Health care utilization characteristics were compared between patients with and without a comorbidity of depression. Propensity score matching was applied to ensure a balanced comparison between the two cohorts. RESULTS: The prevalence of a depression comorbidity was found for 5% of the total RA patients. This comorbidity was associated with 62% (56%) higher total outpatient visits and 66% (163%) higher rate of emergency room visits after 6 (12) months. CONCLUSIONS: Burden of depression among RA patients in Japan is relatively high and awareness for depression as a comorbidity of RA needs to be reinforced. FUNDING: Janssen Pharmaceutical KK.
INTRODUCTION: To determine the cost of depression comorbidity among Japanese adults with rheumatoid arthritis (RA). METHODS: A retrospective database study of 8968 patients diagnosed with RA between 2010 and 2015 and treated with any RA medication was conducted. Health care utilization characteristics were compared between patients with and without a comorbidity of depression. Propensity score matching was applied to ensure a balanced comparison between the two cohorts. RESULTS: The prevalence of a depression comorbidity was found for 5% of the total RApatients. This comorbidity was associated with 62% (56%) higher total outpatient visits and 66% (163%) higher rate of emergency room visits after 6 (12) months. CONCLUSIONS: Burden of depression among RApatients in Japan is relatively high and awareness for depression as a comorbidity of RA needs to be reinforced. FUNDING: Janssen Pharmaceutical KK.
Entities:
Keywords:
Depression; Health care utilization; Japan; Rheumatoid arthritis
Authors: Derek L Mattey; Peter T Dawes; Andrew B Hassell; Ann Brownfield; Jonathan C Packham Journal: J Rheumatol Date: 2010-08-03 Impact factor: 4.666
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Bernd Löwe; Levke Willand; Wolfgang Eich; Stephan Zipfel; Anthony D Ho; Wolfgang Herzog; Christoph Fiehn Journal: Psychosom Med Date: 2004 May-Jun Impact factor: 4.312
Authors: Carol A Hitchon; Randy Walld; Christine A Peschken; Charles N Bernstein; James M Bolton; Renée El-Gabalawy; John D Fisk; Alan Katz; Lisa M Lix; James Marriott; Scott B Patten; Jitender Sareen; Alexander Singer; Ruth Ann Marrie Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794